Crossovers back Aura with $80M as it preps first pivotal test of virus-like particle conjugation tech

An $80 million crossover series E round will support 12-year-old Aura’s first pivotal trial based on its virus-like particle conjugation technology: a Phase III study in choroidal melanoma, an ocular cancer. 

CEO Elisabet de los Pinos told BioCentury that Aura Biosciences Inc. could also start clinical trials in two more indications by the time it has a pivotal readout in its first indication, likely in 2023...